Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice.

NCT03438006 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03438006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03438006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice.
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
May 31, 2018
Completion date
December 3, 2020
Enrollment
3,016 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia